Plasma levels of resistin predict cardiovascular events

Open access

Abstract

Background: A number of cytokines and adipokines secreted by adipose tissue may influence vessel wall directly. Adiponectin exhibits anti-inflammatory and atheroprotective actions. Resistin is expressed at higher levels in inflammatory cells. Resistin directly activates the endothelium through upreglation of adhesion molecules, induces production of TNF-α by macrophages, effects that are antagonized by adiponectin. Leptin has multiple effects on cells of artery walls, many similar to those of resistin. The prognostic role of adipokines in atherosclerosis is not well established. Methods: We compared the baseline plasma levels of adiponectin, resistin, leptin and TNF-α (ELISA assays) in 59 patients with coronary artery disease (CAD) and 32 patients with peripheral artery disease (PAD). Also, we investigated the impact of baseline plasma levels of adiponectin, resistin, leptin and TNF-α on the incidence of the new ischemic cardiovascular events. Results: In patients with CAD, as compared with PAD, baseline plasma levels of leptin were significantly increased (2882.02 ± 368.57pg/ml vs 1025.56 ± 232.28 pg/ml; p<0.001), plasma levels of resistin were significantly decreased (13.15 ± 0.83ng/ml vs 17.76 ± 2.13 ng/ml; p = 0.02) and no differences in plasma levels of adiponectin and TNF-α were found. A significant correlation between BMI and plasma levels was found only for leptin, irrespective of group. 45 patients (49.5%) were re-hospitalized in a 2 years period of follow-up. In a backward stepwise multivariable Cox regression analysis only resistin ≥ 15 ng/ ml, HR =1.8829, 95% CI 1.0490- 3.3797, p = 0.034 and diastolic blood pressure ≥ 85 mmHg, HR =2.0927, 95%CI 1.0782- 4.0616, p=0.0299 were associated with new cardiovascular events. Conclussion: In patients with clinical atherosclerosis plasma levels of resistin predict new ischemc events.

1. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409(6818):307-12. DOI: 10.1038/35053000

2. Wang H, Chu WS, Hemphill C, Elbein SC. Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. J Clin Endocrinol Metab. 2002;87(6):2520-4. DOI: 10.1210/jcem.87.6.8528 DOI: 10.1210/ jc.87.6.2520

3. Adeghate E. An update on the biology and physiology of resistin. Cell Mol Life Sci. 2004;61(19-20):2485-96. DOI: 10.1007/s00018-004-4083-2

4. Stumvoll M, Haring H. Resistin and adiponectin--of mice and men. Obes Res. 2002;10(11):1197-9. DOI: 10.1038/oby.2002.162

5. Vendrell J, Broch M, Vilarrasa N, Molina A, Gomez JM, Gutierrez C, et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res. 2004;12(6):962-71. DOI: 10.1038/ oby.2004.118

6. Milan G, Granzotto M, Scarda A, Calcagno A, Pagano C, Federspil G, et al. Resistin and adiponectin expression in visceral fat of obese rats: effect of weight loss. Obes Res. 2002;10(11):1095-103. DOI: 10.1038/ oby.2002.149

7. Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun. 2005;334(4):1092-101. DOI: 10.1016/j.bbrc.2005.06.202

8. Barnes KM, Miner JL. Role of resistin in insulin sensitivity in rodents and humans. Curr Prot Peptide Sci. 2009;10(1):96-107. DOI: 10.2174/138920309787315239

9. Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun. 2003;309(2):286-90. DOI: 10.1016/j.bbrc.2003.07.003

10. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation. 2003;108(6):736-40. DOI: 10.1161/01. CIR.0000084503.91330.49

11. Steppan CM, Lazar MA. The current biology of resistin. J Intern Med. 2004;255(4):439-47. DOI: 10.1111/j.1365-2796.2004.01306.x

12. Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A, et al. Correlation between serum resistin level and adiposity in obese individuals. Obes Res. 2003;11(8):997-1001. DOI: 10.1038/oby.2003.137

13. de Luis DA, Gonzalez Sagrado M, Conde R, Aller R, Izaola O, Perez Castrillon JL, et al. Relation of resistin levels with cardiovascular risk factors and insulin resistance in non-diabetes obese patients. Diabetes Res Clin Prac. 2009;84(2):174-8. DOI: 10.1016/j.diabres. 2009.01.017

14. Pfutzner A, Langenfeld M, Kunt T, Lobig M, Forst T. Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin Lab. 2003;49(11-12):571-6.

15. Iqbal N, Seshadri P, Stern L, Loh J, Kundu S, Jafar T, et al. Serum resistin is not associated with obesity or insulin resistance in humans. Eur Rev Med Pharmacol Sci. 2005;9(3):161-5.

16. Chen CC, Li TC, Li CI, Liu CS, Wang HJ, Lin CC. Serum resistin level among healthy subjects: relationship to anthropometric and metabolic parameters. Metabolism. 2005;54(4):471-5. DOI: 10.1016/j.metabol. 2004.10.015

17. Pischon T, Bamberger CM, Kratzsch J, Zyriax BC, Algenstaedt P, Boeing H, et al. Association of plasma resistin levels with coronary heart disease in women. Obes Res. 2005;13(10):1764-71. DOI: 10.1038/ oby.2005.215

18. Chen C, Jiang J, Lu JM, Chai H, Wang X, Lin PH, et al. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Am J Physiol Hear Cir Physiol. 2010;299(1):H193-201. DOI: 10.1152/ ajpheart.00431.2009

19. Kougias P, Chai H, Lin PH, Lumsden AB, Yao Q, Chen C. Adipocyte-derived cytokine resistin causes endothelial dysfunction of porcine coronary arteries. J Vasc Surg. 2005;41(4):691-8. DOI: 10.1016/j. jvs.2004.12.046

20. Burnett MS, Lee CW, Kinnaird TD, Stabile E, Durrani S, Dullum MK, et al. The potential role of resistin in atherogenesis. Atherosclerosis. 2005;182(2):241-8. DOI: 10.1016/j.atherosclerosis.2005.02.014

21. Xu W, Yu L, Zhou W, Luo M. Resistin increases lipid accumulation and CD36 expression in human macrophages. Biochem Biophys Res Commun. 2006;351(2):376-82. DOI: 10.1016/j.bbrc.2006.10.051

22. Rizkalla J, Melone M, Zhao A, Rashid S. The pathophysiological role of resistin in impaired lipoprotein metabolism in obesity. Circulation. 2009;120:S529.

23. Calabro P, Samudio I, Willerson JT, Yeh ET. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation. 2004;110(21):3335-40. DOI: 10.1161/01. CIR.0000147825.97879.E7

24. Cohen G, Horl WH. Resistin as a cardiovascular and atherosclerotic risk factor and uremic toxin. Semin Dial. 2009;22(4):373-7. DOI: 10.1111/j.1525-139X.2009.00583.x

25. Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun. 2004;314(2):415-9. DOI: 10.1016/j.bbrc.2003.12.104

26. Sharma R, Kumar C, Gangwani S, Singh Sugga G, Rana AC. Resistin and cardiovascular disorder. Afr J of Pharm Pharmacol. 2011;5(1):5.

27. Lee TS, Lin CY, Tsai JY, Wu YL, Su KH, Lu KY, et al. Resistin increases lipid accumulation by affecting class A scavenger receptor, CD36 and ATP-binding cassette transporter-A1 in macrophages. Life Sci. 2009;84(3-4):97-104. DOI: 10.1016/j.lfs.2008.11.004

28. Li L, Han JL, Mao JM, Guo LJ, Gao W. Association between serum resistin level and cardiovascular events in postmenopausal women with acute coronary syndrome undergoing percutaneous coronary intervention. Clin Med J. 2013;126(6):1058-62.

29. Erer HB, Sayar N, Guvenc TS, Aksaray S, Yilmaz H, Altay S, et al. Prognostic value of serum resistin levels in patients with acute coronary syndrome. Kardiol Pol. 2014;72(2):181-6. DOI: 10.5603/KP.a2013.0086

30. Rosner B. Fundamentals of biostatistics. 5th ed. Pacific Grove, CA: Duxbury; 2000.

31. Zhang MH, Na B, Schiller NB, Whooley MA. Association of resistin with heart failure and mortality in patients with stable coronary heart disease: data from the heart and Soul study. J Card Fail. 2011;17(1):24-30. DOI: 10.1016/j.cardfail.2010.08.007

32. Anfossi G, Russo I, Doronzo G, Pomero A, Trovati M. Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells. Mediators of inflammation. 2010;2010:174341. DOI: 10.1155/2010/174341

33. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive- leptin concentrations in normal-weight and obese humans. N Engl J of Med. 1996;334(5):292-5. DOI: 10.1056/NEJM199602013340503

34. Piemonti L, Calori G, Mercalli A, Lattuada G, Monti P, Garancini MP, et al. Fasting plasma leptin, tumor necrosis factor-alpha receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women: impact on cardiovascular mortality. Diabetes care. 2003;26(10):2883-9. DOI: 10.2337/diacare.26.10.2883

35. Scholze A, Rattensperger D, Zidek W, Tepel M. Low serum leptin predicts mortality in patients with chronic kidney disease stage 5. Obesity (Silver Spring). 2007;15(6):1617-22. DOI: 10.1038/oby.2007.191

36. Sattar N, Wannamethee G, Sarwar N, Chernova J, Lawlor DA, Kelly A, et al. Leptin and coronary heart disease: prospective study and systematic review J Am Coll Cardiol. 2009;53(2):167-75. DOI: 10.1016/j. jacc.2008.09.035

37. Ku IA, Farzaneh-Far R, Vittinghoff E, Zhang MH, Na B, Whooley MA. Association of low leptin with cardiovascular events and mortality in patients with stable coronary artery disease: the Heart and Soul Study. Atherosclerosis. 2011;217(2):503-8. DOI: 10.1016/j. atherosclerosis.2010.10.047

38. Owens CD, Kim JM, Hevelone ND, Hamdan A, Raffetto JD, Creager MA, et al. Novel adipokines, high molecular weight adiponectin and resistin, are associated with outcomes following lower extremity revascularization with autogenous vein. J Vasc Surg. 2010;51(5):1152-9. DOI: 10.1016/j.jvs.2009.12.051

39. Osawa H, Doi Y, Makino H, Ninomiya T, Yonemoto K, Kawamura R, et al. Diabetes and hypertension markedly increased the risk of ischemic stroke associated with high serum resistin concentration in a general Japanese population: the Hisayama Study. Cardiovasc Diabetol. 2009;8:60. DOI: 10.1186/1475-2840-8-60

40. Rajpathak SN, Kaplan RC, Wassertheil-Smoller S, Cushman M, Rohan TE, McGinn AP, et al. Resistin, but not adiponectin and leptin, is associated with the risk of ischemic stroke among postmenopausal women: results from the Women’s Health Initiative. Stroke. 2011;42(7):1813-20. DOI: 10.1161/STROKEAHA. 110.607853

41. Zhang MH, Na B, Schiller NB, Whooley MA. Resistin, exercise capacity, and inducible ischemia in patients with stable coronary heart disease: data from the Heart and Soul study. Atherosclerosis. 2010;213(2):604-10. DOI: 10.1016/j.atherosclerosis.2010.09.015

42. Krecki R, Krzeminska-Pakula M, Peruga JZ, Szczesniak P, Lipiec P, Wierzbowska-Drabik K, et al. Elevated resistin opposed to adiponectin or angiogenin plasma levels as a strong, independent predictive factor for the occurrence of major adverse cardiac and cerebrovascular events in patients with stable multivessel coronary artery disease over 1-year follow-up. Med Sci Monit. 2011;17(1):CR26-32. DOI: 10.12659/MSM.881325

43. Lubos E, Messow CM, Schnabel R, Rupprecht HJ, Espinola-Klein C, Bickel C, et al. Resistin, acute coronary syndrome and prognosis results from the Athero- Gene study. Atherosclerosis. 2007;193(1):121-8. DOI: 10.1016/j.atherosclerosis.2006.05.039

44. Lee SH, Ha JW, Kim JS, Choi EY, Park S, Kang SM, et al. Plasma adiponectin and resistin levels as predictors of mortality in patients with acute myocardial infarction: data from infarction prognosis study registry. Coron Artery Dis. 2009;20(1):33-9. DOI: 10.1097/ MCA.0b013e328318ecb0

45. Efstathiou SP, Tsiakou AG, Tsioulos DI, Panagiotou TN, Pefanis AV, Achimastos AD, et al. Prognostic significance of plasma resistin levels in patients with atherothrombotic ischemic stroke. Clin Chim Acta. 2007;378(1-2):78-85. DOI: 10.1016/j.cca.2006.10.023

46. Pilz S, Weihrauch G, Seelhorst U, Wellnitz B, Winkelmann BR, Boehm BO, et al. Implications of resistin plasma levels in subjects undergoing coronary angiography. Clin Endocrinol. 2007;66(3):380-6. DOI: 10.1111/j.1365-2265.2007.02743.x

47. Hoefle G, Saely CH, Risch L, Koch L, Schmid F, Rein P, et al. Relationship between the adipose-tissue hormone resistin and coronary artery disease. Clin Chim Acta. 2007;386(1-2):1-6. DOI: 10.1016/j.cca.2007.07.001

48. Luc G, Empana JP, Morange P, Juhan-Vague I, Arveiler D, Ferrieres J, et al. Adipocytokines and the risk of coronary heart disease in healthy middle aged men: the PRIME Study. Int J Obes (Lond). 2010;34(1):118-26. DOI: 10.1038/ijo.2009.204

49. Lim S, Koo BK, Cho SW, Kihara S, Funahashi T, Cho YM, et al. Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: the Korean atherosclerosis study (KAS): a 42-month prospective study. Atherosclerosis. 2008;196(1):398-404. DOI: 10.1016/j.atherosclerosis. 2006.11.017

Revista Romana de Medicina de Laborator

Romanian Journal of Laboratory Medicine

Journal Information


IMPACT FACTOR 2018: 0,800
5-year IMPACT FACTOR: 0,655



CiteScore 2017: 0.31

SCImago Journal Rank (SJR) 2018: 0.194
Source Normalized Impact per Paper (SNIP) 2018: 0.306

Cited By

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 196 144 14
PDF Downloads 79 62 10